DE60232244D1 - Nachweis und behandlung von prostatakrebs - Google Patents

Nachweis und behandlung von prostatakrebs

Info

Publication number
DE60232244D1
DE60232244D1 DE60232244T DE60232244T DE60232244D1 DE 60232244 D1 DE60232244 D1 DE 60232244D1 DE 60232244 T DE60232244 T DE 60232244T DE 60232244 T DE60232244 T DE 60232244T DE 60232244 D1 DE60232244 D1 DE 60232244D1
Authority
DE
Germany
Prior art keywords
prostate cancer
prostate
proof
treatment
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60232244T
Other languages
English (en)
Inventor
John L Magnani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glycomimetics Inc
Original Assignee
Glycomimetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycomimetics Inc filed Critical Glycomimetics Inc
Application granted granted Critical
Publication of DE60232244D1 publication Critical patent/DE60232244D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G01N2405/10—Glycosphingolipids, e.g. cerebrosides, gangliosides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
DE60232244T 2001-06-21 2002-06-21 Nachweis und behandlung von prostatakrebs Expired - Lifetime DE60232244D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30025001P 2001-06-21 2001-06-21
PCT/US2002/019851 WO2003000117A2 (en) 2001-06-21 2002-06-21 Detection and treatment of prostate cancer

Publications (1)

Publication Number Publication Date
DE60232244D1 true DE60232244D1 (de) 2009-06-18

Family

ID=23158305

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60232244T Expired - Lifetime DE60232244D1 (de) 2001-06-21 2002-06-21 Nachweis und behandlung von prostatakrebs

Country Status (7)

Country Link
US (3) US7135301B2 (de)
EP (1) EP1410022B1 (de)
JP (1) JP2005514585A (de)
AT (1) ATE430935T1 (de)
AU (1) AU2002315411A1 (de)
DE (1) DE60232244D1 (de)
WO (1) WO2003000117A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135301B2 (en) * 2001-06-21 2006-11-14 Glycomimetics, Inc. Detection and treatment of prostate cancer
AU2008289108C1 (en) 2007-08-17 2024-05-23 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
WO2010053772A2 (en) 2008-10-29 2010-05-14 The Regents Of The University Of California Disease-associated antigens and methods of use thereof
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
DK2678446T3 (en) * 2011-02-24 2017-09-11 Ventana Med Syst Inc Presence of erg gene rearrangements and protein overexpression in low-malignant pin (lg-pin) in prostate biopsies
PT2766048E (pt) 2012-10-12 2015-02-25 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
KR20150104092A (ko) 2012-11-15 2015-09-14 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
CN105209077B (zh) 2013-03-13 2019-06-11 麦迪穆有限责任公司 吡咯并苯并二氮杂卓以及其结合物
EP3415489A1 (de) 2013-10-18 2018-12-19 Deutsches Krebsforschungszentrum Markierte inhibitoren des prostataspezifischen membranantigens (psma), deren verwendung als kontrastmittel und pharmazeutika zur behandlung von prostatakrebs
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
SG11202010469QA (en) 2018-05-23 2020-11-27 Adc Therapeutics Sa Molecular adjuvant
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863713A (en) 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US5227160A (en) * 1988-07-15 1993-07-13 The Biomembrane Institute Monoclonal antibody nuh2 capable of inactivating motility of human sperm, antigen defined by said monoclonal antibody and methods of using said monoclonal antibody and antigen
US6008203A (en) 1995-07-14 1999-12-28 Glycotech Corp. Methods for treatment of EGF receptor associated cancers
US7135301B2 (en) * 2001-06-21 2006-11-14 Glycomimetics, Inc. Detection and treatment of prostate cancer

Also Published As

Publication number Publication date
US20030096327A1 (en) 2003-05-22
AU2002315411A1 (en) 2003-01-08
WO2003000117A3 (en) 2003-11-13
US7135301B2 (en) 2006-11-14
JP2005514585A (ja) 2005-05-19
ATE430935T1 (de) 2009-05-15
US20110027180A1 (en) 2011-02-03
US20070048809A1 (en) 2007-03-01
WO2003000117A2 (en) 2003-01-03
US7727735B2 (en) 2010-06-01
EP1410022A2 (de) 2004-04-21
EP1410022A4 (de) 2005-08-17
EP1410022B1 (de) 2009-05-06

Similar Documents

Publication Publication Date Title
DE60232244D1 (de) Nachweis und behandlung von prostatakrebs
Samuel et al. Association between heroin use, needle sharing and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA
TR200002784T2 (tr) Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar
DE60329165D1 (de) Detektion und/oder beobachtung von synuclein-assoziierten krankheiten
HUP0302332A2 (hu) Génkimutatási eljárás ErbB-antagonistával végzett rákterápiára adott hatékony reakció valószínûségének növelésére
BRPI0411200A (pt) método de tratamento de cáncer, métodos de tratamento de paciente humano, artigo industrializado e kit de tratamento de cáncer
DE69936780D1 (de) Antikörper gegen eine lar-phosphatase untereinheit
ATE462973T1 (de) Diagnose und prävention der krebszellinvasion
DE69907152D1 (de) Krebsbehandlung
HUP0400719A2 (hu) Vegyületek és eljárások Chlamydia-fertőzés diagnosztikájára és kezelésére
TR199902803T2 (xx) VCAM-1' in te�hisinin daralt�lmas� i�in bile�ikler ve metodlar.
DE69941214D1 (de) DIAGNOSE, VORBEUGUNG UND BEHANDLUNG VON ULCERATIVER COLITIS UND DEREN SUBTYPEN UNTER VERWENDUNG MIKROBIELLER UC pANCA ANTIGENE
ATE497165T1 (de) Erkennung eines erhöhten spiegels von her-2/neu- proteinen in zirkulierenden krebszellen und dessen behandlung
TR199902828T2 (xx) Lizofosfolipidlerin de�i�mi� konsantrasyonlar� ile birle�tirilmi� kanser belirleme y�ntemi.
DE60335636D1 (de) Zusammensetzungen und verfahren für die tumordiagnose und behandlung
WO2001065998A3 (en) Methods for the diagnosis and treatment of breast cancer
DE60234958D1 (de) Psoriasin-expression durch brustepithelzellen
DE60232069D1 (de) Formen prostataspezifischer antigene und verfahren zu deren nachweis
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
ATE397090T1 (de) Verfahren und verbindungen zur diagnose von entzündlichen erkrankungen und identifizierung von pharmakologischen mitteln zur behandlung von entzündlichen erkrankungen
ATE412423T1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
ATE387913T1 (de) Xenogene oligo- oder/und polyribonukleotide als mittel zur behandlung von malignen tumoren
HUP0104194A2 (hu) Módszer és készlet foszfatázcélzó toxinok kimutatására
Pinkerton High-risk behaviour
ATE527282T1 (de) Tumor assoziierte antigene

Legal Events

Date Code Title Description
8364 No opposition during term of opposition